Literature DB >> 23043300

Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice.

Christiane Copie-Bergman1, Andrew C Wotherspoon, Carlo Capella, Teresio Motta, Ennio Pedrinis, Stefano A Pileri, Francesco Bertoni, Annarita Conconi, Emanuele Zucca, Maurilio Ponzoni, Andrés J M Ferreri.   

Abstract

The International Extranodal Lymphoma Study Group (IELSG) promoted this study to determine the inter-observer agreement in the application of the Groupe d' Etude des Lymphomes de l' Adulte (GELA) histological scoring system for evaluating residual disease in post-treatment gastric biopsies of patients with gastric Mucosa-Associated Lymphoid Tissue (MALT) lymphoma (GML). Twenty-one patients with Helicobacter pylori -associated GML and treated with anti-H. pylori therapies were considered. A total of 154 biopsy sets from follow-up endoscopic procedures after H. pylori eradication were examined independently by seven pathologists from four European countries, following histological criteria suggested by the GELA scoring system. The overall concordance rate was 83% with a kappa value of 0·64, indicating a significant agreement among the seven observers. Most non-concordant responses clustered across the border of complete remission (CR) and probable minimal residual disease (pMRD), a distinction that does not imply critical clinical impact. Accordingly, when the analysis considered CR/pMRD as a single entity, the responses showed an overall concordance rate of 89% with kappa value of 0·83, thus indicating a high degree of inter-observer agreement. This study provides additional validation of the GELA histological grading system. This scheme can therefore be recommended in routine practice and deserves to be used in prospective clinical trials.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23043300     DOI: 10.1111/bjh.12078

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue.

Authors:  Hui-Jen Tsai; John Jen Tai; Li-Tzong Chen; Ming-Shiang Wu; Kun-Huei Yeh; Chung-Wu Lin; Tsang-En Wang; Hsiu-Po Wang; Fang-Jung Yu; Jyh-Ming Liou; Chin-Fu Hsiao; Tsu-Yao Cheng; Hong-Jen Yeh; Chung-Wang Ko; Ming-Jen Chen; Gin-Ho Lo; Ping-I Hsu; Cheng-Shyong Chang; Wei-Shou Hwang; Shih-Sung Chuang; Hsiao-Wei Lee; Chia-Tung Shun; Chang-Fang Chiu; Wen-Ming Wang; Ching-Yun Hsieh; Tsang-Wu Liu; Jaw-Town Lin; Sung-Hsin Kuo; Ann-Lii Cheng
Journal:  Haematologica       Date:  2019-11-14       Impact factor: 9.941

2.  Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Barbara Kiesewetter; Marlene Troch; Marius E Mayerhoefer; Werner Dolak; Ingrid Simonitsch-Klupp; Markus Raderer
Journal:  Oncologist       Date:  2015-11-30

3.  A roadmap for clinical trial design in marginal zone lymphoma.

Authors:  Juan Pablo Alderuccio; Thomas Habermann; Russ Kuker; Craig H Moskowitz; Andrew D Zelenetz; Izidore S Lossos
Journal:  Am J Hematol       Date:  2022-09-12       Impact factor: 13.265

Review 4.  Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives.

Authors:  Dominic Kaddu-Mulindwa; Lorenz Thurner; Konstantinos Christofyllakis; Moritz Bewarder; Igor Age Kos
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

Review 5.  Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas.

Authors:  Marta-Isabel Pereira; José Augusto Medeiros
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

6.  Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients.

Authors:  Joachim Yahalom; Amy J Xu; Ariela Noy; Stephanie Lobaugh; Monica Chelius; Karen Chau; Carol Portlock; Carla Hajj; Brandon S Imber; David J Straus; Craig H Moskowitz; Morton Coleman; Andrew D Zelenetz; Zhigang Zhang; Ahmet Dogan
Journal:  Blood Adv       Date:  2021-04-13

7.  Gastric mucosa-associated lymphoid tissue (MALT) lymphoma: clinicopathological study and treatment outcome in 50 patients.

Authors:  Yosr Zenzri; Lamia Charfi; Ghada Sahraoui; Yosra Yahyaoui; Karima Mrad; Nadia Boujelbene; Raoudha Doghri
Journal:  Pan Afr Med J       Date:  2020-12-23

8.  First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Sung-Hsin Kuo; Kun-Huei Yeh; Ming-Shiang Wu; Chung-Wu Lin; Ming-Feng Wei; Jyh-Ming Liou; Hsiu-Po Wang; Li-Tzong Chen; Ann-Lii Cheng
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

9.  Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Eun Jeong Gong; Ji Yong Ahn; Hwoon-Yong Jung; Hyungchul Park; Young Bo Ko; Hee Kyong Na; Kee Wook Jung; Do Hoon Kim; Jeong Hoon Lee; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  Gut Liver       Date:  2016-09-15       Impact factor: 4.519

Review 10.  MALT lymphoma: epidemiology, clinical diagnosis and treatment.

Authors:  Petruta Violeta Filip; Denisa Cuciureanu; Laura Sorina Diaconu; Ana Maria Vladareanu; Corina Silvia Pop
Journal:  J Med Life       Date:  2018 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.